Solutions
Advisory Services
Clinical Development
- Generics Development
- Clinical Operations
- Clinical Data Sciences
- Medical and Safety Services
- RWD & RWE Services
Post Marketing
- Safety Services
- Post marketing Studies
- Regulatory Affairs
From Regulatory Necessity to Strategic Advantage AI in Labeling is emerging as an important milestone. After all, labeling has long been one of the most critical yet understated functions in life sciences. For years, its primary mandate was to ensure compliance, reflect approved data accurately and meet regulatory expectations across markets. The w...
In life sciences outsourcing, few terms are used as interchangeably, and as confusingly, as Contract Research Organisation and Clinical Research Organisation. Both are commonly shortened to CRO, both support sponsors across drug development, and both play a critical role in bringing therapies to patients faster. So what actually differentiates a Co...
How AI in Clinical Trials, Decentralized Clinical Trials and Real-World Evidence (RWE) Are Redefining Research Clinical research is entering 2026 with rising complexity and rising expectations. Sponsors are under pressure to accelerate development timelines, manage global operations, meet evolving regulatory requirements and deliver patient-centric...
A Year of Impact 2025 was a year of progress and partnership, where sponsors looked for the best CRO partner for global clinical trials, demanded inspection-ready clinical trial support for EMA inspections and needed teams that could deliver under pressure without compromising quality. Navitas Life Sciences worked alongside partners across clinical...
The Navitas Advantage: Powering the Future of Pharma & Biotech In today’s fast-moving world of pharma and biotech, innovation isn’t just an advantage—it’s a necessity. Scientific breakthroughs, evolving global regulations, and the relentless demand for speed and quality are rewriting the rules of drug development. To...
Pharma’s digital maturity has accelerated recently, and emerging technologies are core enablers of faster R&D. As we move into 2026, five digital technologies stand out as the most transformative in the biopharma industry. 1. Big Data Platforms & Intelligence-Driven RWE Ecosystems Modern R&D relies on the seamless flow of clinica...
PV India 2025 once again proved why it remains one of the most sought-after pharmacovigilance peer networks, bringing together senior drug safety leaders for deep, high-quality discussions and future-ready insights. As one of the most established PV peer networks in India, the forum continues to be recognized for its ability to encourage quality di...
On this World Diabetes Day, we reaffirm our global commitment to reducing the burden of diabetes. Because it embodies the science behind better diabetes care, the euglycemic clamp study stands as one of the most significant innovations in modern diabetes research. The euglycemic clamp is a symbol of precision and by offering an accurate measure of ...
Accelerating First-to-Market Success in Generics Bioavailability and Bioequivalence (BABE) studies are critical gateways to bringing safe, effective, and affordable generic medicines to market. With over 90% of US prescriptions filled by generics, ensuring robust clinical execution and data integrity has never been more important. Digital Precision...
The complexities and challenges of data is increasing at an unprecedented rate and excellence in Clinical Data Management (CDM) has become a defining factor of success. Pharmaceutical and biotech companies are looking for partners who not only manage data but transform it into meaningful insights that drive smarter and more compliant decisions. In ...